Amylin Pharmaceuticals — Proxy Contest (May 2009)
8 slides from Amylin Pharmaceuticals's proxy contest presentation, May 14, 2009
Slide 1: Refuting Eastbourne's Claims
Refuting Eastbourne’s Claims May 2009
Slide 2: Legal Information
2 Legal Information FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements about Amylin. Our actual results could differ materially from those discussed due to a number of factors, including: BYETTA, SYMLIN or exenatide once weekly being affected by competition, safety or o
Slide 3: Eastbourne's Response to FDA Alert
3 Eastbourne’s Response to FDA Alert August 2008 FDA issues safety alert relating to cases of pancreatitis and BYETTA use Amylin and Lilly host conference call on 8/26/08 3/12/2008 Eastbourne requests and receives waiver from Amylin’s shareholder rights plan to increase ownership up to 20% 4/3/2008
Slide 4: Amylin's Response to FDA Alert
4 While clearly unhappy with the recent stock performance, Amylin focuses on factors that it can influence by: Responding to regulatory challenges in timely, evidence-based manner: Rigorous safety program and plan put in place Incidence data published for type 2 diabetes (1) No increase in relative
Slide 5: Eastbourne's Statements Don't Tell the Whole Story
5 Eastbourne’s Statements Don’t Tell the Whole Story Eastbourne Quote Fact “Nominees possess skills, experience, objectivity and judgment to maximize commercial potential of Amylin’s assets” Eastbourne proposes replacing directors with relevant commercial, biopharma, diabetes and regulatory expertis
Slide 6: Eastbourne Is Wrong About BYETTA's Launch
Eastbourne Is Wrong About BYETTA’s Launch Quarterly U.S. Sales Post Launch Relative Sales Analysis Source: Evaluate Pharma and IMS BYETTA ACTOplus met Levemir Januvia Prandin Company: Launch Date: Shionogi Has U.S. Rights, Introduced 30-Jun-98 Amylin & Eli Lilly Takeda 9-Jun-05 1-Nov-05 31-Mar-04 31
Slide 7: Analyzing Eastbourne's Suggested Board Changes
7 Analyzing Eastbourne’s Suggested Board Changes Eastbourne wants to replace significant diabetes, commercial and operational expertise with nominees who have no relevant experience on the eve of the most important product launch in Amylin’s history Who You Lose: Amylin Slate Who You Gain: Eastbourn
Slide 8: Two Strategies: A Study in Contrast
8 No articulated strategic plan Proxy fight where it selected nominees with financial backgrounds and no vital regulatory, commercial, biopharma, or diabetes experience Seeking short-term fix to address significant pressure on portfolio (1) Two Strategies: A Study in Contrast Amylin & Eastbourne agr